Details of the Drug Combination

General Information of Drug Combination (ID: DCOBPZE)

Drug Combination Name

JQ1 Ixazomib

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

JQ1 DM3XQDH

Ixazomib DM5ZVLB

Small molecular drug

N.A.

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 12.902

Bliss Independence Score: 11.224

Loewe Additivity Score: 4.696

LHighest Single Agent (HSA) Score: 8.845

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of JQ1

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]

JQ1 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HUMAN bromodomain-containing protein 2 (BRD2)	TTNISW6	BRD2_HUMAN	Inhibitor	[2]
------------------------------------------------------------------------------------

Indication(s) of Ixazomib

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[3]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Uncovering the Role of BRD2 in COVID-19. 2020-03-19
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015